Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Macrocyclic peptidomimetics as inhibitors of insulin-regulated aminopeptidase (IRAP)
launched July 1, 2026 through December 31, 2027 Who Faces the Greatest Need for This Coverage The groups most likely to benefit from the Medicare GLP-1 Bridge program include: Medicare Part D enrollees ages 65 and older with a body mass index of 35 or higher, or a BMI of 27 or higher combined with a qualifying condition such as cardiovascular disease or prediabetes Adults with obesity who were previously unable to afford brand-name GLP-1 medications on fixed retirement incomes People who discontinued brand-name GLP-1 treatment due to cost and are eligible to re-enter with the $50 Bridge copay Patients managing obesity-related conditions including hypertension, sleep apnea, and prediabetes, who may reduce downstream healthcare costs through weight management People who already receive GLP-1 coverage through their Part D plan for diabetes, cardiovascular disease, or sleep apnea do not qualify for the Bridge program they continue to access the drugs through their existing coverage
Conclusiones La combinacin de agonistas de GLP-1 con GIP y/o GCG representa una estrategia teraputica prometedora para la reduccin del peso corporal en adultos obesos sin diabetes tipo 2
A $840 value
US$ 21.50
US$ 26.54
US$ 26.93
US$ 28.39
